ArticleClinical and translational radiation oncology2026
Outcome and safety of SBRT in centrally and ultra-centrally located lung tumours: A PRISMA-based systematic review and Meta-Analysis.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Stereotactic Body Radiation Therapy (SBRT) offers a curative treatment option for patients with early-stage central and ultra-central lung tumours, however can be associated with severe side effects. This review provides a structured quantitative evaluation of outcomes and safety in these critical locations, therefore offering safety-oriented evidence to support individualised treatment planning. Methods: Pubmed/MEDLINE was searched with the term ["Carcinoma, Non-Small-Cell Lung"[Mesh] AND ("Radiosurgery"[Mesh] OR "SABR" OR "stereotactic ablative radiotherapy" OR "SBRT" OR "stereotactic body radiotherapy")] according to PRISMA-guidelines. Trials reporting on SBRT in central and ultra-central lung tumours and on outcome parameters were included. A Results: 57 retrospective and 12 prospective trials were included, encompassing in total 3,672 and 1,509 patients with central and ultra-central lung tumours. The median follow-up was 22.7 (range: 10.6 - 93.6) months for centrally and 21.2 (8.6 - 93.6) months for ultra-centrally located tumours. For ultra-central lesions the median overall survival was 28.0 (12.0 - 64.5) months compared to 39.4 (19.0 - 57.0) months in central lesions with highest efficacy of SBRT with 60 Gy in 8 fractions. Overall, pooled grade 3-5 toxicity was low for both localizations. The most frequently reported fatal complication in ultra-centrally vs. centrally located tumours was haemorrhage with an estimated proportion of 0.48% [range: 0 - 14.89; CI 95% = 0.00 - 1.68] vs. 0.12% [range: 0 - 7.09; CI 95% = 0.00 - 0.46]. Conclusion: SBRT with 60 Gy in 8 fractions provides a feasible and safe curative treatment approach for patients with centrally and ultra-centrally located lung tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.